|Bid||0.7179 x 800|
|Ask||0.7192 x 1000|
|Day's Range||0.6900 - 0.7540|
|52 Week Range||0.6900 - 5.7600|
|Beta (3Y Monthly)||1.83|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.50|
LAKE FOREST, Ill., Nov. 26, 2019 -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that members of senior management will participate at the 31st Annual Piper.
LAKE FOREST, Ill., Nov. 13, 2019 -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that members of senior management will participate at the Stifel Healthcare.
PDL BioPharma (PDLI) impresses investors with third-quarter earnings beat. LENSAR laser system bumps up sales as well. However, revenues fall year over year.
Assertio (ASRT) delivered earnings and revenue surprises of 4.35% and -6.93%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
-- Company Implements New Cost Savings Initiatives Expected to Deliver Annualized Savings of $20.0 Million -- -- Raises Full-Year 2019 Earnings Guidance Ranges -- -- Lowers.
In 2017 Art Higgins was appointed CEO of Assertio Therapeutics, Inc. (NASDAQ:ASRT). This analysis aims first to...
NEW YORK , Oct. 30, 2019 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 effective prior to the open of trading on Tuesday, November 5 : ...
Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LAKE FOREST, Ill., Oct. 23, 2019 -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that it will release third-quarter 2019 financial results on Wednesday, November.
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 21.) Aprea Therapeutics Inc (NASDAQ: APRE ) AVITA ...
Assertio Therapeutics, Inc. (ASRT), today announced that its development partner West Therapeutic Development, LLC (West) has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for its injectable formulation of long-acting cosyntropin (synthetic adrenocorticotropic hormone, or ACTH). West is seeking approval for use as a diagnostic drug in the screening of patients presumed to have adrenocortical insufficiency. The primary focus of the CRL relates to the FDA determination that certain pharmacodynamic parameters were not adequately achieved.
Biotech stocks continued to languish for a third straight week. Negative broader market sentiment and company-specific weakness weighed down on the sector. Pfenex Inc (NYSE: PFNX ) received FDA approval ...
If you own shares in Assertio Therapeutics, Inc. (NASDAQ:ASRT) then it's worth thinking about how it contributes to...
Assertio Therapeutics, Inc. (ASRT) announced today that Dr. David Wheadon has been appointed to the Company’s Board of Directors. Dr. Wheadon is a former senior executive of AstraZeneca plc. “David is a globally recognized leader in healthcare and we are thrilled to have him join our Board of Directors,” said Arthur Higgins, President and CEO of Assertio.
LAKE FOREST, Ill., Sept. 26, 2019 -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that members of senior management will participate at the Annual Cantor.
TORONTO and HOUSTON , Sept. 24, 2019 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company, today announced the appointment of Ms. Karen Dawes to the Board of Directors of Medicenna and the voting results from the Company's annual meeting of shareholders held today, September 24, 2019 in Toronto (the "Meeting"). A total of 36.15% of the issued and outstanding common shares of the Company were represented in person and by proxy at the Meeting.
As an investor, mistakes are inevitable. But you have a problem if you face massive losses more than once in a while...
LAKE FOREST, Illinois, Aug. 20, 2019 -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that members of senior management will participate at the 17th Annual Morgan.
Director, President and CEO of Assertio Therapeutics Inc (30-Year Financial, Insider Trades) Arthur J Higgins (insider trades) bought 50,000 shares of ASRT on 08/12/2019 at an average price of $1.54 a share. Continue reading...
“We have worked hard to pay down our senior secured debt and with today’s announcement we have taken a significant step toward addressing our 2021 convertible debt. Pursuant to the Exchange Agreements, Assertio will exchange approximately $200 million aggregate principal amount of Exchanged Notes for a combination of (a) its new 5.00% Convertible Senior Notes due August 15, 2024 (the “New Convertible Notes”), (b) a cash payment plus accrued but unpaid interest on the Exchanged Notes, and (c) an agreed number of shares of Assertio’s common stock. The transactions are subject to customary closing conditions and are expected to close on August 13, 2019. The shares of Assertio’s common stock and the New Convertible Notes will be issued in private placements exempt from registration in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). Assertio will issue approximately $120 million aggregate principal amount of New Convertible Notes, pay an aggregate of approximately $30 million in cash and issue an aggregate of approximately 15.8 million shares of its common stock in the transactions.